Riskpilot← Back to searchSign inGet full accessDR. FANEBUST AS
ASActiveOrg 924825340Thueveien 14, 3121 NøtterøyMedical specialists activities · NACE 8622Est. 20201 employees
Revenue 2024
NOK 7,5M
+2% vs 2023
EBITDA margin
47.3%
+9% vs 2023
Equity ratio
66.3%
Financial strength
Net profit 2024
NOK 2,2M
+11% vs 2023
| Revenue | NOK 7,5M | +2% |
| EBITDA | NOK 3,6M | +9% |
| Net profit | NOK 2,2M | +11% |
| Total assets | NOK 7,6M | +17% |
| Equity | NOK 5M | +12% |
| Employees | 1 | — |
Legal name
DR. FANEBUST AS
Org number
924825340
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
24. mars 2020
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene. Daglig leder alene.
Company purpose
Lege, spesialist innen øre-nese-hals og alt som hører naturlig inn under dette. Deltagelse i andre selskaper.
Address
Thueveien 14, 3121 Nøtterøy
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 621 | 6 629 | 6 872 | 7 365 | 7 532 |
| Staff expenses | −648 | −1 511 | −1 533 | −1 664 | −1 611 |
| EBITDA | 2 021 | 3 104 | 3 137 | 3 266 | 3 562 |
| Depreciation & amort. | −372 | −649 | −668 | −600 | −600 |
| EBIT | 1 649 | 2 455 | 2 469 | 2 666 | 2 962 |
| Net financials | −54 | −65 | −90 | −14 | −9 |
| Profit before tax | 1 595 | 2 390 | 2 379 | 2 651 | 2 953 |
| Tax | 351 | 528 | 543 | 638 | 723 |
| Net profit | 1 244 | 1 861 | 1 836 | 2 014 | 2 230 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 037 | 5 166 | 6 500 | 6 461 | 7 569 |
| Equity | 1 274 | 1 335 | 3 171 | 4 485 | 5 015 |
| Long-term debt | 3 102 | 2 949 | 2 500 | 732 | 0 |
| Short-term debt | 661 | 882 | 829 | 1 244 | 2 554 |
| Total debt | 3 763 | 3 831 | 3 329 | 1 976 | 2 554 |
EBITDA margin
47.3%
This company
15.8%
Market median
+199% vs market
20202024
Equity ratio
66.3%
This company
38.2%
Market median
+74% vs market
20202024
Return on equity
44.5%
This company
18.4%
Market median
+142% vs market
20202024
Net profit margin
29.6%
This company
8.1%
Market median
+265% vs market
20202024
Asset turnover
1.00×
This company
1.12×
Market median
+11% vs market
20202024
Debt / equity
0.51×
This company
0.62×
Market median
+18% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-03-10 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DR. FANEBUST AS 
FRITZØE KLINIKK SPESIALISTER ASBoard members of DR. FANEBUST AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Schmidt Blaafjell | Board of Directors | 0 companies |
| Henriette Fanebust | Chairman | 0 companies |